FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
Phase 3 trial shows 51 percent reduction in the risk for disease progression or death in triple-class exposed patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.